Datavault AI

DVLT

Börsenwert 125 Mio. $

Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled "Interim Access Policy for Compounding Using Certain Peptides." The new proposed policy comes less than three months following the recommendation from FDA's Pharmacy Compounding Advisory Committee (PCAC) to loosen restrictions on the use of six peptides.

Allowed patent application covers asset valuation, tokenization, transaction verification, and blockchain-enabled marketplaces as a new federal framework opens the door to on-chain trading of tokenized stocks PHILADELPHIA, PA / ACCESS Newswire / October 15, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its Method and System for Data Futures Platform patent application (U.S. Patent Application No. 17/441,847), and highlighted the relevance of the disclosed technology to a significant development in the regulatory landscape for tokenized securities.

Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. ("REBOOT") for Direct-to-Consumer (DTC) rights in the United States to REBOOT's proprietary care management platform. The Companies will work together to tailor the platform for use in the Health Lives Here mobile application for patients taking GLP-1 receptor agonist medications (the "GLP Management Platform") leveraging the patents and patent applications (the "IP") under the license.

PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served.

CEO Nathaniel T. Bradley to present on tokenization capabilities Today, October 13, at 3:45 p.m.

Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL / ACCESS Newswire / October 13, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx® as a diagnostic lab test to help oncologists inform their chemotherapy regimen selection, initially for gynecologic cancers only.

Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company vertically integrating its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in gynecologic cancers for the ChemoFx® Assay, a commercially available chemoresponse test that measures how a patient's live tumor cells respond to chemotherapy agents, in gynecologic cancers.

PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, digital engagement, real-world asset (“RWA”) tokenization and spatial audio technologies, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovato.

PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, digital engagement, real-world asset (“RWA”) tokenization and spatial audio technologies, today announced the appointment of Christopher R. Hardt to its board of directors as an independent director, effective as of October 3, 2026. Hardt was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavau.

LOS ANGELES--(BUSINESS WIRE)---- $DVLT--DVLT Investor Alert: Schall, Brown & Schwartz LLP Files Expanded Class Action Lawsuit Against Datavault AI, Inc.